Generation Bio Corp (GBIO) - EV/EBITDA Multiple
Generation Bio Co. (GBIO) is a cutting-edge brand developing high-precision DNA systems for the therapy of severe genetic pathologies. This chart illustrates the EV/EBITDA ratio, which currently stands at 0.00. The company serves as a scientific leader in developing safe, redosable drugs, making the process of correcting hereditary disorders more flexible and earning profound respect within the professional community.
GBIO (generationbio.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- market capitalization indicators:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
- net income and valuation multiples indicators:
GBIO - Net Financial Result|Expected Profit Generation Bio Co.|GBIO - Market Cap to Earnings|Projected Price to Earnings Generation Bio|GBIO - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple GBIO|GBIO - Operating profit before deduction of amortization|Earnings per share for the last twelve months Generation Bio|GBIO - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months generationbio.com|GBIO - Expected net earnings per share growth this year|Earnings growth forecast for next year Generation Bio Co.
Fundamental company valuation:Generation Bio Corp (GBIO)
Investors use this criterion to determine the market value of a business relative to its operational efficiency, accounting for debt load. The ratio of enterprise value to earnings before interest, taxes, depreciation, and amortization allows for an assessment of how cell-free DNA synthesis reduces costs for Generation Bio Co. (GBIO), which is clearly reflected in the shift of the EV/EBITDA multiple as production scales.
Key competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tempus.com TEM|Business Value to Operating Income Before Depreciation QGEN|Ionis Pharmaceuticals - EV/EBITDA Multiple|RGEN - EV/EBITDA Multiple|RNA (Avidity Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|CRSP: Enterprise Value to Operating Income Before Depreciation Ratio|WGS (Sema4) - EV/EBITDA Multiple|Ultragenyx Corp (RARE) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Beam Therapeutics Inc. (BEAM)|SRPT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience, Inc. TWST|TXG: Enterprise Value to Operating Income Before Depreciation|NTLA: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation STOK (Stoke Corp)|BLFS: EV/EBITDA Multiple|WVE (wavelifesciences.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MAZE (Maze Therapeutics) - EV/EBITDA Multiple|Sionna Therapeutics, Inc. (SION) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prime Medicine Corp (PRME)|TSHA - Company Value to EBITDA|uniQure N.V. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation MGTX|REGENXBIO - EV/EBITDA Multiple|Solid Biosciences Inc (SLDB) - Enterprise Value to EBITDA Ratio|Ocugen Corp (OCGN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA PacBio Corp (PACB)|Enterprise Value to EBITDA Ratio BNTC|designtx.com (DSGN) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple RCKT|4DMT (FDMT) - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple LXEO (Lexeo Therapeutics, Inc.)|Korro Bio Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Editas Medicine, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio silence-therapeutics.com SLN|proqr.com (PRQR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Codexis (CDXS)|SGMO (Sangamo) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation NAUT (Nautilus Biotechnology Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Metagenomi, Inc. (MGX)|precisionbiosciences.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLD (Boundless Bio)|EV/EBITDA Multiple Exicure Inc. XCUR|Celsion Corporation - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Phio Pharmaceuticals (PHIO)|MBIO: EV/EBITDA Multiple|Company Value to EBITDA TransCode Therapeutics, Inc. (RNAZ)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bionano Genomics Inc.|Enterprise Value to Operating Income Before Depreciation APDN (Applied DNA Sciences Inc)|EV/EBITDA Multiple BLUE|IPA - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omega Therapeutics OMGA|Business Value to Operating Income Before Depreciation OMIC|Regulus Therapeutics Inc. - EV/EBITDA Multiple|SYRS - EV/EBITDA Multiple|TBIO (Codex DNA) - Enterprise Value to EBITDA Ratio|TCON: Enterprise Value to Operating Income Before Depreciation Ratio|UBX (Unity Biotechnology) - EV/EBITDA Multiple
